Dihydrocapsiate NEW
Price | $970 | $1260 | $1910 |
Package | 25mg | 50mg | 100mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Dihydrocapsiate | CAS No.: 205687-03-2 |
Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Dihydrocapsiate |
Description | Dihydrocapsiate is a compound of capsinoid family that can be used in metabolism diseas research. Dihydrocapsiate is an orally active agonist of TRPV1 [1]. |
In vitro | Dihydrocapsiate treatment at concentrations of 10, 25, and 50 μM for 48 hours does not impact the viability of human preadipocytes, indicating its non-toxic nature at these levels [1]. At lower concentrations of 10 and 20 μM, but over a longer period of 8 days, dihydrocapsiate significantly reduces the expression of various adipogenic (like SREBP1, FABP4, PLIN1, ADIPOQ, and LEPTIN) and inflammatory markers (MCP1 and TNFα) in mature adipocytes. Conversely, it increases the expression of PGC1α, crucial for mitochondrial biogenesis, and TBX1, a marker of "brite" cells, highlighting its potential role in adipocyte metabolism and inflammation modulation [1]. Interestingly, in RAW 264.7 cells, dihydrocapsiate concentrations ranging from 25 to 200 μM effectively inhibit the release of nitric oxide (NO) and the generation of intracellular reactive oxygen species (ROS), providing evidence of its anti-inflammatory and antioxidative properties [1]. |
In vivo | Dihydrocapsiate administered orally at doses of 2 and 10 mg/kg effectively improves morphometric parameters and insulin levels in HFD-fed mice [1]. It counteracts the enlargement of adipocytes and upregulates energy expenditure-related genes in white adipose tissue (WAT), mitigates hepatic steatosis, and inhibits fat accumulation prompted by a high-fat diet (HFD). Furthermore, it elevates the expression of mitochondrial biogenesis-related genes in brown adipose tissue (BAT), ameliorates intestinal morphology, and modulates the availability of short-chain fatty acids (SCFAs), showcasing its broad pharmacological potential in metabolic regulation. |
Storage | Shipping with blue ice. |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/25KG |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2024-10-10 | |
$0.00/1KG |
VIP2Y
|
Wuhan Haorong Biotechnology Co.,Ltd
|
2023-08-07 | |
$1.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-09 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY